CLL/SLL
Haematology · 2015–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ibrutinib Treatment of patients with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in combination with venetoclax. | Mar 2024 | Recommended with restriction | 64 individuals Leukaemia Foundation · Lymphoma Australia · Rare Cancers Australia |
| zanubrutinib Relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) considered unsuitable for treatment or retreatment with a purine… | Mar 2023 | Recommended with restriction | 1 individuals Rare Cancers Australia · Lymphoma Australia |
| acalabrutinib Treatment of patients with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), who are considered unsuitable for… | Nov 2021 | Not recommended | input received Rare Cancers Australia · Leukaemia Foundation |
| acalabrutinib First-line treatment of previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients considered unsuitable for… | Jul 2020 | Not recommended | 13 individuals Leukaemia Foundation · Lymphoma Australia · Rare Cancers Australia |
| ibrutinib Treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), and relapsed or refractory mantle cell lymphoma… | Nov 2020 | Recommended | input received Leukaemia Foundation |
| ibrutinib Relapsed or refractory mantle cell lymphoma (MCL); and first-line treatment of patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma… | Mar 2018 | Recommended with restriction | 2 individuals |
| ibrutinib Second-line treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) in patients unsuitable for purine… | Nov 2015 | Deferred | 12 individuals |
Who spoke
Leukaemia Foundation · Rare Cancers Australia · Lymphoma Australia
What the PBS pays
$295M in government benefit over 2024–25, across 37,292 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| zanubrutinib | $136.4M |
| ibrutinib | $85.2M |
| acalabrutinib | $72.9M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 7 of 7 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.